tbuckley/cabot-search huggingface dataset:
Validation of an RT-PCR multi-gene prognostic signature for distant metastasis in node negative (N-), ER positive (ER+) breast cancer patients using FFPE sections
Authors: A. Tutt, A. Wang, R. Springall, K. Lau, K. Ryder, L. Kam Morgan, S. Broder, L. Esserman, C. Gillett, J. Sninsky
Journal: Journal of Clinical Oncology (2007)

21009 Background: We sought to validate a previously developed 14-gene prognostic signature and a metastasis score (MS) that predicted distant metastasis in N-, ER+ breast cancer patients in an independent sample set of patients without systemic treatment. The genes consisted primarily of proliferation genes involved in p53 and TNF signaling pathways. Methods: : A cohort of 294 N-, ER+ breast cancer patients from Guy's Hospitals, London, UK without systemic therapy were tested. The cohort had a mean age of 55.5 yrs with 49% &gt; 55 yrs, mean tumor size of 1.93 (max. 3) cm, and a median follow up of 14.3 yrs. The primary endpoint was distant metastasis free survival. RT-PCR was carried out on fixed sections. The MS was calculated. Results: The mean MS (SD) was 0.44 (0.59) with a range of -1.31 to 2.0. Hazard of distant metastasis increased 3.02 fold (95% CI 1.91–4.76, p &lt;0.0001) per unit increase in MS from Cox model. The pre-determined cut point of zero was used to stratify patients into low- and high-risk groups. The 5-yr distant-metastasis-free survival rate (DMFSR) for low- and high-risk groups were 1 and 0.86 (SE 0.024); the 10-yr DMFSR were 0.97 (0.021) and 0.77 (0.030), respectively. Univariate Cox regression analyses indicated that MS (hazard ratio (HR) 5.65, 95% CI 2.05–15.56, p=0.008), tumor size (HR 1.62, p=0.0047) and tumor grade (HR 2.52, p=0.036) were significant but age was not. Multivariate Cox regression indicated that the signature had independent prognostic value with a HR of 4.71 (1.42–15.61, p=0.011) after adjusting for age, tumor size and grade. AUC of MS at 5-and 10-yr were 0.78 (0.71–0.85, p&lt;0.001) and 0.73 (0.66–0.80, p&lt;0.001) with sensitivities of 1 and 0.96 and specificities of 0.31 and 0.31 at zero cut point, respectively. The differential risk between the median MS scores of the lowest and highest deciles was 8-fold. Conclusions: A previously defined RT-PCR prognostic signature for N-, ER+ patients has been confirmed. A metastasis score that quantifies distant metastasis risk, not confounded with treatment effect can complement treatment response predictors. Insight on natural history of tumors is critical for evaluating impact of therapy. No significant financial relationships to disclose.
Immune-mediated viral clearance from the CNS without collateral damage
Authors: Christoph Konradt, Christopher A. Hunter
Journal: The Journal of Experimental Medicine (2015)

![Figure][1] 

Insight from Christoph Konradt (left) and Christopher Hunter (right)



The events that lead to the control of many infections are frequently associated with immune-mediated collateral damage to surrounding cells and tissues. Nowhere is this more apparent than in the central
Surgery for obstructive sleep apnea: Sleep endoscopy determinants of outcome
Authors: Ioannis Koutsourelakis, Madeline Ravesloot, Emmanouil Vagiakis, Spyros Zakynthinos, Nico de Vries
Journal: European Respiratory Journal (2012)

Although drug-induced sleep endoscopy (DISE) is often employed in order to determine the site of obstruction in patients with obstructive sleep apnea (OSA) who will undergo upper airway surgery, it remains unknown whether its findings are associated with surgical outcome. This study tested the hypothesis that DISE variables can predict the outcome of upper airway surgery.

Forty-nine OSA patients [41 men; mean apnea-hypopnea index (AHI) 30.9±18.5 events/h] underwent firstly DISE, secondly upper airway surgery, and thirdly follow-up polysomnography to assess surgical outcome.

Twenty-three patients (47%) were responders and twenty-nine non-responders (53%). Non-responders had a higher occurrence of complete or partial circumferential collapse at velum, and of complete antero-posterior collapse at tongue base or epiglottis, in comparison with responders. Multivariate logistic regression analysis revealed that, among baseline clinical characteristics and DISE findings, the presence of complete circumferential collapse at velum, and of complete antero-posterior collapse at tongue base were the only independent predictors of upper airway surgery failure.

![Figure][1] 



Patterns of collapse on DISE associated with failure. A. complete circumferential collapse at velum. B. complete antero-posterior collapse at tongue base C. complete antero-posterior collapse at epiglottis.

In conclusion, DISE findings are predictors of upper airway surgery outcome in OSA.

 [1]: pending:yes
Early sexual experience and prostitution
Authors: J James, J Meyerding
Journal: American Journal of Psychiatry (1977)

The authors compared several aspects of early sexual experience found in two earlier studies of prostitutes with results of research on "normal" women. The prostitutes had in common many negative experiences not found or found less often in other populations of young women. These include incestuous and/or coerced sex, lack parental guidance, intercouse at a young age, and few or no meaningful relationships with males. These women had discovered that sex could lead to a kind of status, even though that status is negatively labeled by the wider culture. In a society that values women on the basis of their sexuality, a woman who views herself as "debased" may see prostitution as a viable alternative--perhaps the only alternative.
Resection Rate with Folfirinox-Based Neoadjuvant Therapy in Locally Advanced/Borderline Resectable Pancreatic Cancer: a Pooled Analysis of Published Data
Authors: F. Petrelli, A. Coinu, K.F. Borgonovo, M. Ghilardi, M. Cabiddu, M. Cremonesi, V. Lonati, S. Barni
Journal: Annals of Oncology (2014)
Nasal pressure measurements in the presence of a proprietary nasal expiratory positive airway pressure (EPAP) device
Authors: Stephen Milne, Manisha Verma, Rita Perri, Terence C. Amis, John R. Wheatley, Kristina Kairaitis
Journal: European Respiratory Journal (2013)

Introduction:  The response characteristics of the Provent® nasal pressure cannula (PNPC), used in recent trials of Provent® therapy for obstructive sleep apnoea, are unknown.  Hypothesis:  PNPC will have different response characteristics to a standard NPC.  Methods:  Airflow was generated through a model of the human nasal passages. Nasal pressure (P) was recorded via pressure transducer with either Provent®+PNPC or a standard NPC. Airflow (V) was recorded simultaneously via pneumotachograph. For a constant flow rate (bidirectional air pump, 0 to ±1 L/s), P/V plots were created and power functions fitted. For respiratory airflow (human subject, tidal breaths), breath amplitudes from airflow (ΔV) and pressure (ΔP) traces were measured and hypopnoeas (>50 percent reduction in amplitude from a reference breath) quantified.  Results : Expiratory flow: P = 0.96V 1.92  (NPC) and P = 24.31V 1.64  (PNPC). Inspiratory flow: P = 1.1V 1.93  (NPC) and P = 2.40V 2.17  (PNPC). dP/dV was greater for PNPC compared to NPC. Using a reference breath of V = -0.4 to +0.2 L/s, the sensitivity and specificity of NPC for the detection of hypopnoeas were 100% and 44%, and for PNPC were 100% and 0%, respectively. Using a smaller reference breath of V = -0.3 to +0.1 L/s, the sensitivity and specificity of NPC were 100% and 33%, and for PNPC were 100% and 47%, respectively.  Conclusion : For any given airflow, P and dP/dV are greater for PNPC than NPC (particularly during expiration). The sensitivity for the detection of breath amplitude changes is also greater with PNPC than with NPC. We conclude that the detection of hypopnoeas with Provent®+PNPC is dependent on the size of the chosen reference breath.
Second-line chemotherapy with weekly paclitaxel and gemcitabine in platinum-etoposide pretreated patients with small cell lung cancer (SCLC): A single institution phase II trial
Authors: V. Dongiovanni, L. Buffoni, D. Dongiovanni, A. Addeo, C. Barone, C. Fissore, R. Grillo, P. Lista, O. Bertetto
Journal: Journal of Clinical Oncology (2004)

7209 Background: Paclitaxel and gemcitabine are active drugs in SCLC. Preliminary analysis suggest that weekly paclitaxel yields in non-small-cell lung cancer patients equivalent efficacy results, maintains dose intensity. Methods: We tested the activity of their combination with a weekly schedule of paclitaxel in a phase II trial as second-line chemotherapy. In this trial progressing patients after first-line treatment with platinum-etoposide were treated with paclitaxel 80 mg/m2 days 1,8,15 and gemcitabine 1000 mg/m2 days 1 and 8 every three weeks. Eligibility criteria were: progressive disease after first-line chemotherapy, age < 75 years, adequate haematological, hepatic and renal function. Results: Between 7/1999 and 2/2003 we enrolled 31 patients. Pts characteristics: male/female: 24/7; ECOG PS 0/1/2: 3/20/8; median age: 64 years (range 48–68); LD/ED: 5/26; prior thoracic/brain radiotherapy was administered in 17 and 5 pts, respectively; chemotherapy-free interval was ≤3 months in 10 pts (32%) and >3 months in 21 pts (68%). A total of 106 cycles were given with a median number of 3 cycles per patient. Median dose intensity for paclitaxel was 58 mg/m2/week (72% of planned dose) and for gemcitabine 553 mg/m2/week (83% of planned dose). Partial responses were observed in 8 pts (26%), stable disease in 5 (16%) and progression in 18 (58%). In refractory and sensitive pts RR was 20 and 29%, respectively. Toxicity: neutropenia G3–4 in 26% and 0% of pts, thrombocytopenia G3–4 in 22% and 3%; G3–4 asthenia in 13%; G1–2 neurophaty in 32%. Median time to progression was 9.6 weeks. Median survival time was 7.4 months. Conclusions: This weekly schedule of paclitaxel and gemcitabine is an active second-line chemotherapy in SCLC and is very well tolerated. The low dose intensity of paclitaxel could be related to previous radiation therapy in 70% of pts. It seems non-cross resistant with cisplatin or carboplatin and etoposide combination and warrant further evaluation in the
Un score de Glasgow/Blatchford élevé a l’admission est associé à un risque élevé de récidive hémorragique après la sortie des patients hospitalisés pour hémorragie digestive haute
Journal: Endoscopy (2015)

Le score de Glasgow/Blatchford est un score validé pour prédire le recours à une intervention en cas d’hémorragie digestive et la mortalité hospitalière. Il n’a jamais été étudié dans l’intérêt d’évaluer le devenir des malades après leur sortie de l’hôpital.
Abstract 19118: Symptom Predictors of Delayed ST-Elevation Myocardial Infarction Presentation
Authors: Pawan Hari, Maithili Shenoy, Tanya Doctorian, David Choe, Amar Desai, Daniel Sufficool, Brian Khan, Minh-Tri Pham, Steven Shadix, Tankazyan Hambik, Hwinei Tavengwa, Stoletniy Liset, Anthony Hilliard
Journal: Circulation (2014)

Introduction: Through various systematic initiatives, cardiac centers routinely reach targeted door-to-balloon (DTB) treatment times of less than 90 minutes resulting in improved outcomes. However, in an effort to further optimize outcomes, by reducing total ischemic time, focus on symptom onset and their impact on presentation is needed. Hypothesis: This study aimed to identify whether the type and nature of specific symptoms are associated with delays in presentation in STEMI patients. Methods: 549 patients with complete data presenting with STEMI from April 2008 to December 2012 to a tertiary hospital were retrospectively studied. False activations were excluded. 449 patients were included in this analysis. Symptom-onset-to-hospital arrival time (symptom-onset time was identified by review of medical records, pre-hospital emergency services data and by interviewing patient’s and their family) was analyzed for the following factors: type of symptoms (chest pain, dyspnea, cardiac arrest) and nature of symptoms (constant or intermittent). Non-parametric univariate and multivariate analyses (PROC GLIMMIX) were carried out using Statistical Analysis Systems version 9.1 (SAS Institute, Cary, NC) statistical software package. Results: See table Conclusion: As expected, STEMI patients presenting with cardiac arrest who survived pre-hospital resuscitation presented the fastest, while patients with dyspnea had a significantly longer delay than patients with chest pain. Patients with intermittent symptoms presented significantly later than those with constant symptoms. Of particular interest, symptom-onset-to-door presentation remains long even with the classical symptom of constant chest pain (the most common STEMI symptom presentation). Thus, continued and enhanced population education and awareness is necessary to see further significant decreases in total ischemic time in STEMI patients.
The Effect of Vitamin D Levels on Pediatric Allergic Diseases: A Nationwide Population-Based Study
Authors: Hea-Kyoung Yang, Jaehee Choi, Woo Kyung Kim, So-Yeon Lee, Yong Mean Park, Man-Yong Han, Myung-Il Hahm, Yoomi Chae, Hye-young Kim, Kang Mo Ahn, Ho-Jang Kwon, Jihyun Kim
Journal: Journal of Allergy and Clinical Immunology (2016)
Chemotherapy in patients with nonresectable cancer of the biliary system or advanced gallbladder cancer: Do elderly have benefit at all?
Authors: R. Dobrilla-Dintinjana, I. Djipalo, D. Stimac, M. Dintinjana
Journal: Journal of Clinical Oncology (2005)

4268 Introduction: Adenocarcinomas of the bile ducts (BSCa) and gallblader (GBCa) are highly malignant neoplasms with a very poor prognosis. Chemotherapy (cht) often plays only a palliative role and responses are transient without prolonged survival. Aim of the study: To evaluate effectiveness of gemcitabine (G) and cisplatin (CP) combination protocol in achieving Clinical Benefit Response (CBR) for patients (pts) with nonresectable BSCa and with advanced GBCa and to evaluate the differences between younger and elderly pts. For this type of tumors we took 60 years as bordeline for elderly. Results: During four years period we cured 30 pts with BSCa and GBCa with mean age of 50,4+5,4 years. There was 18 females with mean age of 48,2+4,6 years, and 12 men with mean age 52,6+4,6 years. In the group of elderly there was 6 females with mean age of 60,5+2,8 years, and 4 men with mean age of 61,8+2,6 years. 20 pts (66,7%) had locally advanced disease and 10 pts (33,3%) metastatic disease. Pts achieved G 1000 mg/m2 intravenous once per week for seven times. CP 100 mg/m2 iv was administered at day 1,15,29 and 43. Number of applicated cycles was 1–10 (median 4 cycles). Partial response rate achieved 18 pts-60%. All pts-100% achieved CBR. Pain measured at VAS scale before cht was 4,8; and after 1st cht cycle 1,6. Karnofsky Performance Status before cht was 60%, and after 1st cycle 80%. Median duration Clinical Benefit was 22 weeks. 50% of pts developed nausea gradus II (WHO); elderly developed more serious leucopenia and trombocitopenia (gradus III) than younger (gradus II). Conclusions: There was no difference between younger and elderly pts in number of applicated cycles; also no difference in achieving partial response rate and CBR. There was difference in developing side effects; elderly had more serious leucopenia and trombocitopenia than younger. This results indicate that the treatment of GBCa and BSCa with gemcitabine and cisplatinum is effective, well tolerated also to elderly pts and leads to Clinical Benefit. We can also confirm thet the role of cht is not only prolonging survival time but also palliation and achieving better Quality of Life. No significant financial relationships to disclose.
Randomized, phase II trial comparing continuous versus intermittent capecitabine (X) monotherapy for metastatic breast cancer (MBC): Results from the GEICAM 2009−05 study.
Authors: M. Martin, N. Martinez, M. Ramos, L. Calvo, A. Lluch, P. Zamora, M. Munoz-Mateu, D. Caronia, E. M. Carrasco, J. Á. Garcia Saenz, A. Casado, I. Chacón, B. Hernando, M. Ruiz-Borrego, A. Gonzalez-Neira
Journal: Journal of Clinical Oncology (2011)

1008 Background: X, 1,250 mg/m2 bid, d1–14 q21d (Xint) is an approved regimen in MBC, but is associated with dose-limiting toxicities. Thus, we designed this randomized phase II study to investigate whether continuous dosing of X (Xcont) could reduce the severity of side effects while maintaining the total cumulative dose and efficacy. Methods: Pts with evaluable MBC, normal organ function, ECOG PS ≤2 and ≤2 prior regimens in the metastatic setting were eligible and randomized to X 800 mg/m2 bid, d1–21 q21d Xcont or Xint q3w. Study endpoints: safety (CTCAE v2.0), TTP, ORR, PFS, DOR, OS. Results: 196 pts were randomized to Xcont (n=99) or Xint (n=97) until progression or unacceptable toxicity. Baseline characteristics were balanced between Xcont and Xint with a median age of 60 yrs (29−88); 21% and 22% were hormone receptor negative; 20% and 16% had prior neoadjuvant chemo; adjuvant therapy had been administered in 76% and 77%, respectively; 56% had visceral involvement in each arm. X was administered as first-line in 45% and 36% of pts, respectively. Prior anthracyclines plus taxanes had been administered to 80% and 89%, in Xcont and Xint, respectively. This preliminary analysis is based on the ITT population: Best RECIST ORR was 29% and 25%, with Xint and Xcont, respectively. Median PFS: 244 vs 187 days (HR 0.69, 95% CI 0.46–1.05), respectively. The relationship between X-induced HFS and 13 polymorphisms in the genes involved in the drug metabolism and target gene (the carboxylesterase 2, cytidine deaminase, thymidine phosphorylase, dihydropyrimidine dehydrogenase gene and thymidylate synthase) will be reported. Grade 3/4 toxicities that differ between groups are reported in the table. Conclusions: The ongoing evaluation suggests that Xcont has a lower incidence of related AEs. It is too early to draw any conclusion about efficacy, mature data will be presented at the meeting. P value Grade ≥ 3 AE Pts with toxicity % ←Xcont Xint→ Xint N=86 Xcont N=84 1.000 Any toxicity 96 96 0.660 HFS 32 35 0.032 Diarrhea 17 6 0.018 Mucositis 12 2 0.284 Fatigue 11 6 0.013 Neutropenia 8 0
Glycine Inhibition of L-Asparagine Amidohydrolase Activity2
Authors: Swaraj K. Chattopadhyay, W. Stephen Matthews, Harry D. Brown
Journal: JNCI Journal of the National Cancer Institute (1973)

L-Asparagine amidohydrolase obtained from guinea pig liver in vitro was competitively inhibited by glycine. Km and K1 were 7.0×10−3M and 4.O×10−3M, respectively. This observation may relate to a published report that glycine antagonizes the therapeutic value of L-asparaginase in vivo.
In search of the true amok: amok as viewed with the Malay culture
Authors: J E Carr, E K Tan
Journal: American Journal of Psychiatry (1976)

In an attempt to discover how the phenomenon of amok is viewed within its indigenous culture, the authors studied and interviewed 21 subjects in West Malaysia who were labeled as amok. This investigation showed that both the subjects and the Malay culture view amok as psychopathology, that amok cases are disposed of in line with this view, and that the behavior of the amok person conforms to social expectations of the phenomenon. Despite cultural proscriptions, however, the act is purposive and motivated and is subtly sanctioned by Malay society.
A phase II trial of perifosine in patients with advanced renal cell carcinoma (RCC) who have failed tyrosine kinase inhibitors (TKI)
Authors: D. C. Cho, R. A. Figlin, K. T. Flaherty, D. Michaelson, J. A. Sosman, M. Ghebremichael, M. E. Bowers, J. W. Mier, M. B. Atkins, D. F. McDermott
Journal: Journal of Clinical Oncology (2009)

5101 Background: The recently demonstrated activity of inhibitors of TORC1 in RCC has raised the possibility that even greater effects may be achieved by targeting upstream of this pathway. Perifosine is a synthetic alkylphospholipid which inhibits Akt activity and also has cell-dependent effects upon the MAP-kinase pathway. Prior single-agent trials showed disease stabilization/regression in patients (pts) with advanced RCC; however, few pts were previously treated with a TKI. Therefore, we conducted a multi-center phase II trial to determine the safety and efficacy of perifosine in pts with advanced RCC refractory to VEGFR TKI. Methods: Primary objectives were to measure the % of pts progression-free at 12 weeks (wks) and overall progression-free survival (PFS) of perifosine (100 mg qhs). Secondary objectives included overall response rate (&gt; PR), and safety, Eligibility: ECOG PS 0–1, pts with metastatic RCC who have RECIST defined progression on either sunitinib or sorafenib. Prior Rx with immunotherapy and bevacizumab was permitted. Normal organ and marrow function required. Results: From 4/07–10/08, 24 pts were treated at four sites. Median age 67 (range 47–78) and 16 were male; 90% of pts had predominantly clear cell histology. Prior sunitinib = 12; prior sorafenib = 12 (1.5 avg prior Rx). As of 12/08, all 24 pts were evaluable for PFS, response and toxicity as follows in the table . 6/24 pts remain on treatment (range 7 - 84 wks). Therapy was well tolerated with primarily Grade (G) 1 &amp; 2 adverse events. G 3 &amp; 4 events were: dyspnea (8%), hyponatremia (8%), pulmonary embolism (4%) and arthalgia (4%). Conclusions: Perifosine has promising activity in pts with RCC who have failed prior TKI therapy. The favorable toxicity profile suggests potential for combinational therapies with VEGF-targeted agents. Additional studies are under consideration to evaluate perifosine for clinical benefit in pts with previously treated RCC. [Table: see text] [Table: see text]
Body mass index in acute heart failure: association with clinical profile, therapeutic management and in-hospital outcome
Authors: John Parissis, Dimitrios Farmakis, Nikolaos Kadoglou, Ignatios Ikonomidis, Ekaterini Fountoulaki, Erifili Hatziagelaki, Spyridon Deftereos, Ferenc Follath, Alexandre Mebazaa, John Lekakis, Gerasimos Filippatos
Journal: European Journal of Heart Failure (2016)
Improvement of islet engrafts by enhanced angiogenesis and microparticle-mediated oxygenation
Authors: Leila Montazeri, Shahriar Hojjati-Emami, Shahin Bonakdar, Yaser Tahamtani, Ensiyeh Hajizadeh-Saffar, Marjan Noori-Keshtkar, Mostafa Najar-Asl, Mohammad Kazemi Ashtiani, Hossein Baharvand
Journal: Biomaterials (2016)
A phase I/II dose-escalation study of weekly paclitaxel in combination with 5'-deoxy-5-fluorouridine for advanced or recurrent breast cance
Authors: H. Iwata, M. Mizutani, K. Kamei, T. Toyama, Y. Ando, D. Ota, N. Kawaguchi, C. Shigemori, H. Iwase
Journal: Journal of Clinical Oncology (2004)

698
Activation of Guinea Pig C-Type Virus in Cultured Spleen Cells by 5-Bromo-2′-deoxyuridine&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: G. D. Hsiung
Journal: JNCI Journal of the National Cancer Institute (1972)

Guinea pig C-type virus particles were activated by exposure of primary spleen cells of leukemic animals to a medium containing 40 µg/ml 5-bromo-2′-deoxyuridine (5-BUDR) for 48–72 houn. Abundant C-type virus particles, approximately 110 mµ, were seen in spleen cultures treated with 5-BUDR but were seldom found in parallel cultures without drug treatment. Virus particles were observed in both intracytoplasmic and extracellular spaces. Occasionally budding virus particles were found at the cell surface.